Basics NovoCure Limited Ordinary Shares NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. IPO Date: September 28, 2015 Sector: Healthcare Industry: Medical Instruments and Supplies Market Cap: $1.36B Activated in VL: True Average Daily Range Avg Daily Range: $1.30 | 2.69% Avg Daily Range (30 D): $0.29 | 2.39% Avg Daily Range (90 D): $0.27 | 2.20% Institutional Daily Volume Avg Daily Volume: .8M Avg Daily Volume (30 D): 1.51M Avg Daily Volume (90 D): 1.47M Trade Size Avg Trade Size (Sh.): 72 Avg Trade Size (Sh.) (30 D): 69 Avg Trade Size (Sh.) (90 D): 77 Institutional Trades Total Inst.Trades: 5,081 Avg Inst. Trade: $3.59M Avg Inst. Trade (30 D): $2.15M Avg Inst. Trade (90 D): $2.75M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5.41M Avg Closing Trade (30 D): $2.18M Avg Closing Trade (90 D): $2.24M Avg Closing Volume: 109.24K     News Sep 29, 2025 @ 8:30 PM Novocure to Present Final Results from the Pivotal... Source: Business Wire Aug 29, 2025 @ 8:26 AM 2 Beaten-Down Stocks That Could Rocket 142% to 222... Source: Cory Renauer Jul 24, 2025 @ 1:21 PM Novocure: Steady Ahead of Key Milestones Source: Lou Whiteman Apr 24, 2025 @ 1:25 PM NovoCure Surpasses Q1 Expectations Source: Jesterai Apr 16, 2025 @ 7:43 PM Why NovoCure Stock Was Withering on Wednesday Source: Eric Volkman Financials   TTM Q3 2025 Q2 2025 Basic EPS $-1.61 $-.33 $-.36 Diluted EPS $-1.61 $-.33 $-.36 Revenue $ 642.27M $ 167.2M $ 158.81M Gross Profit $ 484.08M $ 122.48M $ 117.33M Net Income / Loss $ -177.65M $ -37.27M $ -40.14M Operating Income / Loss $ -176.71M $ -36.02M $ -39.52M Cost of Revenue $ 158.19M $ 44.73M $ 41.47M Net Cash Flow $ 155.44M $ 192.51M $ 22.7M PE Ratio